What is it about?
Our findings suggest that in multiple sclerosis patients the treatment of psychological problems 6 to 9 months after start of injectable disease modifying drug treatment may positively affect treatment persistence, and that home care and informal care may promote treatment adherence. We obtained no evidence that persistence of and adherence to disease-modifying treatment are associated with the amount of neurological, nursing, pharmaceutical, or rehabilitative care.
Featured Image
Why is it important?
The identification and treatment of psychological problems in MS patients 6 to 9 months after the start of disease modifying drug treatment might enhance patients' the chances of treatment continuation. Similarly, home care and informal care might promote the adherence to the dosing schedule.
Perspectives
To be optimally effective disease modifying treatment in MS, as in other chronic disorders, requires the long term use of medication and the application of the agreed dosing scheme. Our study results may guide future research about the effect of psychological care on treatment persistence, and of informal and home care on the adherence to the dosing scheme.
Peter J. Jongen
Rijksuniversiteit Groningen
Read the Original
This page is a summary of: Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines, Patient Preference and Adherence, May 2016, Dove Medical Press,
DOI: 10.2147/ppa.s108121.
You can read the full text:
Contributors
The following have contributed to this page
